{"url_path":"/sec/drma/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operation and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-037124-index.html","accession_number":"0001493152-26-037124","cik":"0001853816","ticker":"DRMA","issuer_name":"Dermata Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-037124-index.html","primary_entity_key":"0001853816","primary_entity_name":"Dermata Therapeutics, Inc."},"word_count":168,"has_tables":true,"body_markdown":"**Item\n2.02. Results of Operation and Financial Condition.**\n\n \n\nOn\nAugust 11, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding\nits results of operations for the quarter ended June 30, 2026, and provided a corporate update. A copy of the press release is furnished\nunder Item 2.02 as Exhibit 99.1.\n\n \n\nThe\ninformation included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed”\nfor the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the “Exchange\nAct”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange\nAct made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference\ninto any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such\nfiling."}